{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:23:50Z","timestamp":1793903030262,"version":"4.8.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The objective of this study was to compare and rank the efficacy and safety of different thrombopoietin receptor agonists (TPO-RAs) in the treatment of chemotherapy-induced thrombocytopenia (CIT) among patients with solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PubMed, Cochrane Library, Embase, MEDLINE, Web of Science,\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , CNKI, Wanfang Database, VIP Database, SinoMed, and China Drug Trials (\n                      <jats:ext-link>www.chinadrugtrials.org.cn<\/jats:ext-link>\n                      ) were searched for randomized controlled trials (RCTs) of TPO-RAs for CIT in solid tumors from the inception to 31 December 2024. The Cochrane Risk of Bias Assessment Tool 2 was used for assessing the risk of bias. We performed a random-effects network meta-analysis using STATA 14.0 software. Treatments were ranked according to the surface under the cumulative ranking curve. Confidence of the evidence was assessed using Confidence in Network Meta-Analysis. The study protocol was registered with PROSPERO (number CRD42024612536).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of eight studies (568 patients) were included. Most RCTs (7\/8) showed a low risk of bias. The confidence in evidence was often low or very low. Our network meta-analysis indicates that when compared with placebo, hetrombopag (summary RR 0.45, 95% confidence interval 0.28\u20130.73) and eltrombopag (0.57, 0.41\u20130.81) significantly reduced the incidence of chemotherapy dose reduction or delay due to thrombocytopenia. Hetrombopag (0.29, 0.13\u20130.68) also significantly reduced the platelet transfusions. Eltrombopag had the lowest risk for bleeding event (0.41, 0.13\u20131.23) and mortality (0.83, 0.48\u20131.44). There were no significant differences in the risk of adverse events (AEs) between interventions. Hetrombopag (0.37, 0.02\u20138.68) showed the least risk of thrombosis. According to rankograms, hetrombopag was ranked as the best for reducing the incidence of chemotherapy dose reduction or delay, and platelet transfusions, with the least risk of serious AEs and thrombosis. Eltrombopag carried the least risk of bleeding events and mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our network meta-analysis suggested that based on the limited indirect data, hetrombopag may represent the preferred therapy for avoiding chemotherapy dose reductions or delays and platelet transfusion. Eltrombopag may be considered the preferred therapeutic option for avoiding bleeding events and mortality. Both compounds have acceptable safety profiles. However, larger head-to-head trials are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024612536<\/jats:ext-link>\n                      , identfier CRD42024612536.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1683857","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:26:53Z","timestamp":1764570413000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Yingyu","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianni","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhencong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqian","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists","volume":"63","author":"Al-Samkari","year":"2024","journal-title":"Blood Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Al-Samkari","year":"2022","journal-title":"Lancet Haematol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2174\/0115734129317614240809053901","article-title":"Metabolic profiling techniques and their application in cancer research","volume":"20","author":"Alwahsh","year":"2024","journal-title":"Curr. Pharm. Anal."},{"key":"B4","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ajh.24011","article-title":"Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study","volume":"90","author":"Brynes","year":"2015","journal-title":"Am. J. Hematol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000452992","article-title":"A 2-Year, longitudinal, prospective Study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia","volume":"137","author":"Brynes","year":"2017","journal-title":"Acta Haematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS One"},{"key":"B7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40360-023-00707-5","article-title":"Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis","volume":"24","author":"Chen","year":"2023","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3760\/cma.j.issn.0253-3766.2018.09.014","article-title":"Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)","volume":"40","year":"2018","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1514231","DOI":"10.3389\/fphar.2025.1514231","article-title":"The clinical effect and safety of non-pharmacological Chinese medicine therapy in treating chronic nonspecific low back pain: a systematic review and network meta-analysis protocol","volume":"16","author":"Cui","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B11","article-title":"Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced thrombocytopenia","volume-title":"Subjects with relapsed ovarian cancer (2nd or further line)","author":"Euctr","year":"2014"},{"key":"B12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3324\/haematol.2013.098921","article-title":"Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up","volume":"99","author":"Ghanima","year":"2014","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.1994.12.11.2317","article-title":"Clinical impact of chemotherapy-induced thrombocytopenia in patients with gynecologic cancer","volume":"12","author":"Goldberg","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"436","DOI":"10.6004\/jnccn.2022.0026","article-title":"NCCN guidelines\u00ae insights: hematopoietic growth factors, version 1.2022","volume":"20","author":"Griffiths","year":"2022","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B16","article-title":"NCCN Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors. Version 1.2025","volume":"22","author":"Griffiths","year":"2024","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/sim.5957","article-title":"A refined method for multivariate meta-analysis and meta-regression","volume":"33","author":"Jackson","year":"2014","journal-title":"Stat. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"Kellum","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3324\/haematol.2021.279512","article-title":"Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies","volume":"107","author":"Kuter","year":"2022","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/blood-2009-05-224766","article-title":"Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim","volume":"114","author":"Kuter","year":"2009","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1182\/blood.v98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/S1359-6349(09)71939-1","article-title":"Safety of romiplostim for treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with advanced non-small cell lung cancer (NSCLC)","volume":"7","author":"Natale","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1080","DOI":"10.1002\/cl2.1080","article-title":"CINeMA: software for semiautomated assessment of the confidence in the results of network meta-analysis","volume":"16","author":"Papakonstantinou","year":"2020","journal-title":"Campbell Syst. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"17588359241260985","DOI":"10.1177\/17588359241260985","article-title":"Hetrombopag for the management of chemotherapy-induced thrombocytopenia in patients with advanced solid tumors: a multicenter, randomized, double-blind, placebo-controlled, phase II study","volume":"16","author":"Qin","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e99682","DOI":"10.1371\/journal.pone.0099682","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"9","author":"Salanti","year":"2014","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","first-page":"640578","DOI":"10.3389\/fimmu.2021.640578","article-title":"Platelet-Mediated protection of cancer cells from immune surveillance - possible implications for cancer immunotherapy","volume":"12","author":"Schmied","year":"2021","journal-title":"Front. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/ejh.13595","article-title":"The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies","volume":"106","author":"Shaw","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.bmt.1700747","article-title":"Serum thrombopoietin levels in patients undergoing autologous peripheral blood stem cell transplantation","volume":"19","author":"Shimazaki","year":"1997","journal-title":"Bone Marrow Transpl."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1200\/JCO.18.01931","article-title":"Romiplostim treatment of chemotherapy-induced thrombocytopenia","volume":"37","author":"Soff","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e0257673","DOI":"10.1371\/journal.pone.0257673","article-title":"Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia","volume":"17","author":"Soff","year":"2022","journal-title":"PLoS One"},{"key":"B34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1080\/17474086.2023.2201428","article-title":"Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia","volume":"16","author":"Song","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1111\/bjh.20037","article-title":"Chemotherapy-induced thrombocytopenia: modern diagnosis and treatment","volume":"206","author":"Song","year":"2025","journal-title":"Br. J. Haematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B37","first-page":"3607","article-title":"A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy","volume":"87","author":"Tepler","year":"1996","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"B40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/cam4.326","article-title":"Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study","volume":"4","author":"Winer","year":"2015","journal-title":"Cancer Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017","journal-title":"Int. J. Hematol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1683857\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T06:26:57Z","timestamp":1764570417000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1683857\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":41,"alternative-id":["10.3389\/fphar.2025.1683857"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1683857","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"article-number":"1683857"}}